SOPH

NASDAQ

SOPHiA GENETICS SA

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2021

News25/Ratings12

Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.

News · 26 weeks107+84%

2025-10-262026-04-19

Mix9390d

Insider74(80%)
SEC Filings10(11%)
Other6(6%)
Earnings3(3%)

Latest news

25 items

2dINSIDER
SEC Form 4 filed by Van Well Daan
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dINSIDER
SEC Form 4 filed by Xu Zhenyu
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dINSIDER
SEC Form 4 filed by Valente Manuela
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dINSIDER
SEC Form 4 filed by Menu Philippe
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dINSIDER
SEC Form 4 filed by Camblong Jurgi
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dINSIDER
SEC Form 4 filed by Muken Ross
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dINSIDER
SEC Form 4 filed by Puylaert Kevin
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
2dPR
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the websi
3dSEC
SEC Form 144 filed by SOPHiA GENETICS SA
144 - SOPHiA GENETICS SA (0001840706) (Subject)
7dINSIDER
SEC Form 4 filed by Camblong Jurgi
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
7dINSIDER
SEC Form 4 filed by Xu Zhenyu
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
7dINSIDER
SEC Form 4 filed by Menu Philippe
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
7dINSIDER
SEC Form 4 filed by Muken Ross
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
7dPR
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SAN DIEGO and NEW YORK, April 16, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™
9dINSIDER
SEC Form 4 filed by Xu Zhenyu
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
9dINSIDER
SEC Form 4 filed by Van Well Daan
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
9dINSIDER
SEC Form 4 filed by Camblong Jurgi
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
9dINSIDER
SEC Form 4 filed by Muken Ross
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
9dINSIDER
SEC Form 4 filed by Menu Philippe
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
13dINSIDER
SEC Form 4 filed by Van Well Daan
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
13dINSIDER
SEC Form 4 filed by Xu Zhenyu
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
13dINSIDER
SEC Form 4 filed by Valente Manuela
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
13dINSIDER
SEC Form 4 filed by Menu Philippe
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
13dINSIDER
SEC Form 4 filed by Muken Ross
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
13dINSIDER
SEC Form 4 filed by Camblong Jurgi
4 - SOPHiA GENETICS SA (0001840706) (Issuer)